[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343573-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343573-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","immunomodulatory-effects-of-trastuzumab-deruxtecan-through-the-cgas-sting-pathway-in-gastric-cancer-cells-research-open-access","Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells - Research Open Access","","Trastuzumab deruxtecan (T-DXd) shows clinical efficacy in HER2-positive gastric cancers, yet its immunomodulatory mechanism remains insufficiently defined. This study evaluates immune-related mechanisms of T-DXd in gastric cancer cells. The agent induces DNA damage and apoptosis across diverse HER2 expression levels, elevating PD-L1. RNA-Seq identifies immune pathway modulation with increased inflammation and IFN signaling. T-DXd activates cGAS-STING and triggers an IFN-I response, promoting dendritic cell activation and enhancing CD8+ T cell–dependent PBMC-mediated tumor cell killing, supporting rationale for combining T-DXd with immune checkpoint blockade in gastric cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/immunomodulatory-effects-of-trastuzumab-deruxtecan-through-the-cgas-sting-pathway-in-gastric-cancer-cells-research-open-access/343573/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/immunomodulatory-effects-of-trastuzumab-deruxtecan-through-the-cgas-sting-pathway-in-gastric-cancer-cells-research-open-access/343573.png","ImageObject",300,407,{"name":42,"@type":43},"Sage","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does trastuzumab deruxtecan (T-DXd) affect gastric cancer cells?","Question",{"text":63,"@type":64},"T-DXd induces DNA damage and apoptosis, producing potent antitumor effects across different HER2 expression levels.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What immune signaling pathways are activated by T-DXd?",{"text":68,"@type":64},"T-DXd increases PD-L1 expression and activates immune-related pathways, including the cGAS-STING axis that drives an IFN-I response.",{"name":70,"@type":61,"acceptedAnswer":71},"How does T-DXd contribute to enhanced anti-tumor immunity?",{"text":72,"@type":64},"Through a cancer-cell intrinsic cGAS-STING–IFN axis, T-DXd activates dendritic cells and enhances PBMC-mediated tumor killing via CD8+ T cells.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343573,1790240823,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":33,"preview_urls":146},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Oh et al. Cell Communication and Signaling (2024) 22:518  \n[https://doi.org/10.1186/s12964-024-01893-3](https://doi.org/10.1186/s12964-024-01893-3)  \nCell Communication and Signaling  \n RESEARCH Open Access  \nImmunomodulatory effects oftrastuzumab   deruxtecan through the cGAS-STING pathway in gastric cancer cells  \nKyoung‑Seok Oh 1, Ah‑Rong Nam 1, Ju‑Hee Bang 1, Yoojin Jeong1, Sea Young Choo1, Hyo Jung Kim 1, Su In Lee 1, Jae‑Min Kim 1,2, Jeesun Yoon3, Tae‑Yong Kim 1,3 and Do‑Youn Oh 1,2,3*  \nAbstract  \nAlthough the efficacy of trastuzumab deruxtecan (T‑DXd) against HER2‑positive gastric cancers (GCs) has driven its clinical application, the precise mechanisms governing its immunomodulatory role remain unclear. In this study, we examined the immune‑related mechanisms of action ofT‑DXd in GC cells. T‑DXd exhibited potent antitumor effects in GC cells across diverse HER2 expression levels by inducing DNA damage and apoptosis. Activation of the DNA dam‑ age response by T‑DXd led to increased PD‑L1 expression. RNA‑Seq analysis revealed that T‑DXd modulated immune‑ related pathways, resulting in the upregulation of genes associated with inflammation and IFN signaling. Importantly, T‑DXd activated the cGAS‑STING pathway, inducing an IFN‑I response in HER2‑positive GC cells. Furthermore, T‑DXd activated dendritic cells via the cancer cell‑intrinsic cGAS‑STING‑IFN axis and enhanced PBMC‑mediated tumor cell killing by activating CD8+ T cells. These findings provide valuable insights into the role of the cytosolic DNA sensing pathway in the action ofT‑DXd and offer a compelling rationale for combining T‑DXd with immune checkpoint block‑ ade therapies in GC treatment.  \nKeywords ErbB‑2, Trastuzumab deruxtecan, DNA damage, cGAS‑STING signaling, Type‑1 IFN  \nBackground  \nHER2 is a key therapeutic target in gastric and gastroesophageal junction cancers, with approximately 20% of patients classified as HER2-positive (IHC3+ or IHC2+ and ISH+) [1]. Trastuzumab-deruxtecan (T-DXd), a HER2-targeted antibody–drug conjugate (ADC), consists of an anti-HER2 monoclonal antibody linked to a topoisomerase-I (TOP1) inhibitor payload via a cleavable  \n*Correspondence: Do‑Youn Oh [ohdoyoun@snu.ac.kr](ohdoyoun@snu.ac.kr)  \n1 Cancer Research Institute, Seoul National University College of Medicine, 101 Daehak‑Ro, Jongno‑Gu, Seoul 03080, Korea  \n2 Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul 03080, Korea  \n3 Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Korea  \ntetrapeptide-based linker, with a drug-to-antibody ratio of approximately 8 [2, 3]. T-DXd has demonstrated superior antitumor efficacy and overall survival benefits inpatients with gastric cancer (GC), particularly in those previously treated with trastuzumab [4]. Additionally, T-DXd also shows promising clinical efficacy in patients with HER2-low (IHC2+/ISH-or IHC1+) GC, addressing the unmet medical needs of patients with limited therapeutic options [5].  \nClinical trials have demonstrated the efficacy of immune checkpoint inhibitors (ICIs), particularly in combination with chemotherapy, for GC [6–8]. Combining conventional targeted therapies like trastuzumab with ICIs has emerged as a promising strategy to enhance immune responses by reshaping the tumor microenvironment (TME) and expanding the patient population  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative ","cbCaijO2vGWp3gSW","https://ap.wps.com/l/cbCaijO2vGWp3gSW","pdf",3095009,16,"English","# Abstract\n# Background\n## HER2 as a therapeutic target in gastric cancer\n## Mechanistic context for T-DXd and immune checkpoint inhibition\n# Clinical rationale and preclinical evidence","[{\"question\":\"How does trastuzumab deruxtecan (T-DXd) affect gastric cancer cells?\",\"answer\":\"T-DXd induces DNA damage and apoptosis, producing potent antitumor effects across different HER2 expression levels.\"},{\"question\":\"What immune signaling pathways are activated by T-DXd?\",\"answer\":\"T-DXd increases PD-L1 expression and activates immune-related pathways, including the cGAS-STING axis that drives an IFN-I response.\"},{\"question\":\"How does T-DXd contribute to enhanced anti-tumor immunity?\",\"answer\":\"Through a cancer-cell intrinsic cGAS-STING–IFN axis, T-DXd activates dendritic cells and enhances PBMC-mediated tumor killing via CD8+ T cells.\"}]","Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells - Research Open Access | PDF",1790051463,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/863f1bb978084556c195bae6c2c38195.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3432abf3e2283e97780a7867540e297.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8922e28e96c9403aea9d8e01026b0e64.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d7fcced339c4bbb637f93e33fcea1513.webp",980,1301]